Escitalopram is one of a serotonin-reuptake
inhibitors (SSRIs) described for depression
during pregnancy and lactation. Although
many studies refer that exposure to SSRI in
early pregnancy, increase abnormal
disorders, including anencephaly,
craniosynostosis, omphalocele,
cardiovascular abnormalities, septal defects
in certain limb reduction, anal atresia, cystic
kidney, hypospadias, clubfoot, and
undescended testis more studies needed
concerning safety during pregnancy. The
purpose of our study was to find if
escitalopram is linked to increased risk for
foetuses’ skeletal disorders and analyse gene
expression of RSPO2, HAO1 and RUNX2
genes in foetus’s bone. According to the
present results, a significant decrease in
groups 1,2,3,4 for HAO1 gene was reported,
the expression values of HAO1 gene were
downregulated by - 1.66, - 0.96, - 0.95, and -
0.47 respectively comparing with control.
RSPO2 gene expression showed a significant
difference in groups 1 - 4 in comparison with
control group. The expression of RSPO2 gene
was remarkably decreased in (G2) and (G3)
by - 3.057, - 0.253. The expression values of
RUNX2 gene were downregulated by - 0.07
and - 0.04 in (G1) and (G4), respectively and
significantly increased in (G2) when compared
with control. Maternally and paternally treated
foetuses with escitalopram exhibited
shortness of some bones and reduced
ossification of others. Bones and cartilages of
foetuses of groups 3 and 4 were the most
affected by escitalopram.
|
